SML3109

Afatinib

≥98% (HPLC)

• Synonym(e): (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]­-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide, (S,E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, BIBW 2992, BIBW-2992, BIBW2992
• Empirische Formel (Hill-System): C₂₄H₂₅ClFN₅O₃
• CAS-Nummer: 850140-72-6
• Molekulargewicht: 485.94
• MDL-Nummer: MFCD12407405
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: CN(C)C/C=C/C(NC1=CC(C(NC2=CC=C(C(Cl)=C2)F)=NC=N3)=C3C=C1O[C@H]4CCOC4)=O
• InChI: 1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
• InChIKey: ULXXDDBFHOBEHA-CWDCEQMOSA-N

Beschreibung

Biochem./physiol. Wirkung

Afatinib (BIBW2992) is an orally active, irreversible, potent and selective EGFR/HER2 (ErbB2) dual inhibitor (EGFR IC50 = 0.5 nM (Wt), 0.4 nM (L858R), 10 nM (L858R/T790M); HER2 IC50 = 14 nM) that covalently targets EGFR Cys773 and HER2 Cys805 residues. BIBW2992 suppresses 100 ng/mL EGF-induced EGFR/HER2 tyrosin phosphorylation (IC50 = 13-71 nM; A431, NIH-3T3-HER2, BT-474, NCI-N87), inhibits cancer cells survival in cultures and induces tumor regression in xenograft and transgenic lung cancer models in vivo (20 mg/kg/day p.o.).

Sicherheitshinweise

• Piktogramme: GHS08,GHS07
• Signalwort: Warning
• H-Sätze: H302,H319,H373
• P-Sätze: P260 - P264 - P270 - P301 + P312 - P305 + P351 + P338 - P314
• Gefahreneinstufungen: Acute Tox. 4 Oral - Eye Irrit. 2 - STOT RE 2
• Zielorgane: Kidney,Skin
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable